en · de · es · pt
methods-notes.peptides4800.com › Info › Identity And Reported Background — Reference Sheet

Identity And Reported Background — Reference Sheet

By Editorial Desk · published 2025-08-20 · last reviewed 2025-09-24 · Info

The short version of thymosin beta-4 fits in a sentence. The long version — which is the one that helps — is below.

Reviewed 2025-09-24. Anything still debated is marked as such rather than presented as settled.

Identity and Reported Background

Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.

Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.

Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.

TB-500 Identity and Naming Background

Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.

TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.

Tb-500 at a glance

PropertyValueNotes
Reported sequenceAc-LKKTETQDescribed in most listings as the actin-binding region of thymosin beta-4
Reported molecular weightApproximately 889 DaValue shifts with the stated sequence; compare against the certificate of analysis
Parent protein length43 amino acidsThymosin beta-4; the fragment covers only a small part of it
Common synonymsTB4 fragment; thymosin beta-4 fragmentTrade-style names rather than formal nomenclature
Formal monographsNot establishedLabeling conventions differ by supplier and region

Handling, Storage, and Analysis

Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.

Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.

Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.

Related pages on this site

Thymosin Beta-4 Fragment Background

TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.

Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.

Background from the literature

=== Enzyme kinetics === Using the thermodynamic data from ITC, it is possible to deduce enzyme kinetics including proton or electron transfer, allostery and cooperativity, and enzyme inhibition. Modern ITC instruments can measure heat rates as small as 0.1 μcal/sec, allowing for the precise determination of reaction rates in the range of 10−12 mol/sec and ITC can determine values for Km and kcat, in the ranges of 10−2–103 μM and 0.05–500 sec−1, respectively. ITC collects data over time that is useful for any kinetic experiments, but especially with the proteins due to constant aliquots of injections. In terms of calculation, equilibrium constant and the slopes of binding can be directly utilized to determine the allostery and charge transfer, by comparing experimental data of different conditions (pH, use of mutated peptide chain and binding sites, etc.). Kinetic data obtained from ITC have been found to closely align with results from other purely kinetic methods, such as surface plasmon resonance.

== Production == Artificial nanoparticles can be created from any solid or liquid material, including metals, dielectrics, and semiconductors. They may be internally homogeneous or heterogenous, e.g. with a core–shell structure. There are several methods for creating nanoparticles, including gas condensation, attrition, chemical precipitation, ion implantation, pyrolysis, hydrothermal synthesis, and biosynthesis.

While the federal constitution assigns local authorities to the exclusive jurisdiction of state governments, in practice, the federal Ministry of Housing and Local Government oversees the regulation of local laws and policies. Mayors (or presidents for municipal and district councils) and councillors are appointed by the respective state governments, or in the case of the federal territories, by the federal government. Federal laws assign land matters, including the delineation of districts, to the purview of state governments. Except Perlis and the federal territories, each state is divided into districts, which are further subdivided into mukims. In Sabah and Sarawak, districts are grouped into divisions. In contrast to local governments that manage municipal administration and infrastructure development, districts are solely utilised for land taxation. The 13 states are based on historical Malay kingdoms, and 9 of the 11 Peninsular states, known as the Malay states, retain their royal families. The King is elected by and from the nine rulers to serve a five-year term. This King appoints governors serving a four-year term for the states without monarchies, after consultations with the chief minister of that state. Each state has its written constitution. Sabah and Sarawak have considerably more autonomy than the other states, most notably having separate immigration policies and controls, and unique residency status.

Dopamine β-hydroxylase (DBH), also known as dopamine β-monooxygenase, is an enzyme (EC 1.14.17.1) that in humans is encoded by the DBH gene. Dopamine β-hydroxylase catalyzes the conversion of dopamine to norepinephrine.

=== Edrophonium test === This test requires the intravenous administration of edrophonium chloride or neostigmine, drugs that block the breakdown of acetylcholine by cholinesterase (acetylcholinesterase inhibitors). This test is no longer typically performed, as its use can lead to life-threatening bradycardia (slow heart rate) which requires immediate emergency attention. Production of edrophonium was discontinued in 2008.

Sources: en.wikipedia.org

Further detail

If references are made, the Court of Justice will give a preliminary ruling, in order for the member state court to conclude the case and award a remedy. The right to an effective remedy is a general principle of EU law, enshrined in the Charter of Fundamental Rights article 47. Most of the time Regulations and Directives will set out the relevant remedies to be awarded, or they will be construed from the legislation according to the practices of the member state. It could also be that the government is responsible for failure to properly implement a Directive or Regulation, and must therefore pay damages. In Francovich v Italy, the Italian government had failed to set up an insurance fund for employees to claim unpaid wages if their employers had gone insolvent, as the Insolvency Protection Directive required. Francovich, the former employee of a bankrupt Venetian firm, was therefore allowed to claim 6 million Lira from the Italian government in damages for his loss. The Court of Justice held that if a Directive would confer identifiable rights on individuals, and there is a causal link between a member state's violation of EU and a claimant's loss, damages must be paid. The fact that the incompatible law is an Act of Parliament is no defence. So, in Factortame it was irrelevant that Parliament had legislated to require a quota of British ownership of fishing vessels in primary legislation.

==== More Teachers ==== In January 2025, the "More Teachers" program was launched with the aim of increasing the presence of teachers in regions farther from the country's main urban centers. The program provides monthly scholarships of 2,100 reais to teachers with specific training who work in regions with a greater shortage of professionals, such as in the areas of physics, mathematics and biology. The program includes integrated actions to strengthen teacher training, encourage entry into public teaching, and enhance the professional recognition of educators. A National Teacher Examination will be implemented to assist states, the Federal District and municipalities in recruitment and hiring processes for teaching positions, and the Pé-de-Meia Licensure Scholarship will aim to promote entry into, retention in and completion of teacher training courses.

==== Reward circuitry ==== NOP is highly expressed in every node of the mesocorticolimbic reward circuitry. Unlike MOP agonists such as codeine and morphine, NOP agonists do not have reinforcing effects. Nociceptin is thought to be an endogenous antagonist of dopamine transport that may act either directly on dopamine or by inhibiting GABA to affect dopamine levels. In animal models, the result of NOP activation in the central nervous system has been shown to eliminate conditioned place preference induced by morphine, cocaine, alcohol, and methamphetamine.

== Interactions == The actions and effects of muscimol may be potentiated by benzodiazepines such as diazepam. Diazepam has been found to strongly potentiate the central depressant effects of muscimol in rodents. Conversely, the barbiturate phenobarbital did not potentiate the effects of muscimol in rodents. Neurosteroids like allopregnanolone and pregnanolone may potentiate the effects of muscimol.

Sources: en.wikipedia.org

Frequently asked questions

What is TB-500 made of?

Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.

Is TB-500 the same as thymosin beta-4?

No. Thymosin beta-4 is a protein of 43 amino acids, while TB-500 is described as a short fragment of it. The two differ in size, structure, and the range of interactions each can support.

Why do product descriptions differ between suppliers?

Naming for research peptides is not centrally coordinated, so vendors set their own labels and specifications. Differences in stated sequence, molecular weight, or purity documentation usually trace back to those independent labeling choices.

Is TB-500 the same as thymosin beta-4?

No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.

Network